Publicacións en colaboración con investigadores/as de Universitat de Barcelona (29)

2024

  1. Exploring Biginelli-based scaffolds as A2B adenosine receptor antagonists: Unveiling novel structure-activity relationship trends, lead compounds, and potent colorectal anticancer agents

    Biomedicine and Pharmacotherapy, Vol. 173

  2. Stepwise Structural Simplification of the Dihydroxyanthraquinone Moiety of a Multitarget Rhein-Based Anti-Alzheimer Lead to Improve Drug Metabolism and Pharmacokinetic Properties

    Pharmaceutics, Vol. 16, Núm. 8

2023

  1. A Robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery

    Molecules, Vol. 28, Núm. 24

  2. Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs

    Biomedicine and Pharmacotherapy, Vol. 164

2022

  1. A New Family of Subnanomolar inhibitors of Soluble Epoxide Hydrolase

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 36

  2. Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 236

  3. Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease

    Journal of Medicinal Chemistry, Vol. 65, Núm. 6, pp. 4909-4925

  4. Insights into the Pharmacokinetics and In Vitro Cell‐Based Studies of the Imidazoline I2 Receptor Ligand B06

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  5. Soluble Epoxide Hydrolase Inhibitors: Design, Synthesis, in vitro Profiling and in vivo Evaluation in Murine Models of Pain

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 36

  6. Synthesis, In Vitro Profiling, and In Vivo Evaluation of Benzohomoadamantane-Based Ureas for Visceral Pain: A New Indication for Soluble Epoxide Hydrolase Inhibitors

    Journal of medicinal chemistry, Vol. 65, Núm. 20, pp. 13660-13680

2021

  1. 2-(Piperidin-4-yl)acetamides as Potent Inhibitors of Soluble Epoxide Hydrolase with Anti-Inflammatory Activity

    Pharmaceuticals, Vol. 14, Núm. 12

  2. Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 222

  3. From the Design to the in Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis

    Journal of Medicinal Chemistry, Vol. 64, Núm. 9, pp. 5429-5446

  4. From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects

    European Journal of Medicinal Chemistry, Vol. 225

2020

  1. 2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: In Vivo Evaluation in a Murine Model of Acute Pancreatitis

    Journal of medicinal chemistry, Vol. 63, Núm. 17, pp. 9237-9257

  2. A novel NMDA receptor antagonist protects against cognitive decline presented by senescent mice

    Pharmaceutics, Vol. 12, Núm. 3

  3. Bicyclic α-Iminophosphonates as High Affinity Imidazoline I2 Receptor Ligands for Alzheimer's Disease

    Journal of Medicinal Chemistry, Vol. 63, Núm. 7, pp. 3610-3633

  4. Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6

    Journal of Medicinal Chemistry, Vol. 63, Núm. 17, pp. 9360-9390

  5. Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer’s Disease

    Neurotherapeutics, Vol. 17, Núm. 4, pp. 1825-1835

  6. Pharmacology and preclinical validation of a novel anticancer compound targeting PEPCK-M

    Biomedicine and Pharmacotherapy, Vol. 121